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Increased pulmonary vascular esistance may greatly complicate the peri- 
operative management of cardiac surgical patients. Inhaled nitric oxide 
may be a promising new therapy to selectively lower pulmonary vascular 
resistance. The purpose of this study was to examine the effects of inhaled 
nitric oxide on pulmonary and systemic hemodynamics in cardiac surgical 
patients. Twenty patients (age 57 --- 6 years) were studied in the operating 
room after weaning from cardiopulmonary b pass. Mean pulmonary artery 
pressure, pulmonary vascular esistance, systemic vascular esistance, and 
mean aortic pressure were determined at four points of data collection: 
before nitric oxide, with 20 ppm nitric oxide, with 40 ppm nitric oxide, and 
after nitric oxide. Statistical analysis was by analysis of variance; signifi- 
cance was accepted for p < 0.05. Inhaled nitric oxide produced selective 
pulmonary vasorelaxation. Pulmonary vascular resistance was lowered 
from 343 -+ 30 before nitric oxide to 233 -+ 25 dynes, sec -1" cm -s with 
20 ppm nitric oxide. Pulmonary vascular resistance was not further 
lowered by 40 ppm nitric oxide (p < 0.05). Mean pulmonary arterial 
pressure was 29 _ 1 mm Hg before nitric oxide and was lowered to 22 -+ 1 
mm Hg by 20 ppm nitric oxide and 21 - 1 mm Hg by 40 ppm nitric oxide 
(p < 0.05). Both pulmonary vascular resistance and mean pulmonary 
arterial pressure returned to baseline after withdrawal of inhaled nitric 
oxide. Inhaled nitric oxide produced no changes in either systemic vascular 
resistance or mean aortic pressure. We conclude that nitric oxide may be 
used as an effective pulmonary vasodilator after cardiac operations. It may 
be particularly valuable for selectively lowering right ventricular afterload 
in patients with right ventricular dysfunction. (J THORAC CARDIOVASC SURG 
1996;111:753-63) 
I ncreased pulmonary vascular resistance (PVR) may greatly complicate perioperative management 
of cardiac surgical patients. Because PVR is the 
primary clinical determinant of right ventricular 
afterload, increased PVR may result in right ven- 
tricular afterload mismatch, compromising cardiac 
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output (CO). Pharmacologic agents currently used 
as pulmonary vasodilators produce vasodilation of 
both the systemic and pulmonary circulations. Such 
nonselective vasodilation may be hazardous in pa- 
tients with increased PVR 1' 2; significant hypoten- 
sion may result if the degree of systemic vasodilation 
exceeds that of the pulmonary vasodilation. 
When administered to patients with adult respi- 
ratory distress syndrome (ARDS), inhaled nitric 
oxide (NO) has been shown to improve oxygenation 
and to lower PVR. 3' 4 It has also been shown to 
lower PVR in pediatric cardiac surgical patients 
with pulmonary hypertension. 5 We therefore hy- 
pothesized that NO would effectively vasodilate the 
pulmonary circulation without producing unwanted 
systemic vasodilation in adult cardiac surgical pa- 
tients. 
The purpose of this study was to examine the 
pulmonary and systemic hemodynamic effects of 
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Fig. 1. Experimental protocol. After separation from car- 
diopulmonary bypass and administration of protamine, 
LAP monitoring catheter was placed. Baseline hemody- 
namic data were collected, and inhaled NO was then 
administered. Data were collected after 20 and 40 ppm 
NO. Hemodynamic data were collected after withdrawal 
of NO. CABG, Coronary artery bypass grafting; LAP, 
LAP monitoring catheter. 
inhaled NO in adults after cardiac operations. Pa- 
tients undergoing aorta-coronary bypass operations 
were studied in the operating room while under 
general anesthesia. Inhaled NO was administered in 
two concentrations, 20 and 40 ppm. The results of 
this study demonstrate that inhaled NO effectively 
reduced PVR and mean pulmonary arterial pressure 
(MPAP) without affecting systemic vascular resis- 
tance (SVR) or systemic arterial pressure (SAP). 
These data suggest hat inhaled NO may be used 
clinically in adult cardiac surgica ! patients as a 
"selective" pulmonary vasodilator to optimize pul- 
monary hemodynamics without adverse systemic 
hemodynamic effects. 
Methods 
This protocol was approved by the Human Subjects 
Review Committee of the University of Colorado Health 
Sciences Center and the Research and Development 
Committee, Human Subjects Subcommittee of the Den- 
ver Veterans Affairs Medical Center. Informed consent 
was obtained from each participant. 
Administration of inhaled NO. Inhaled NO was sup- 
plied in tanks of 800 to 2200 ppm (Scott Medical Products, 
Plumsteadville, Pa.) and was administered into the in- 
spiratory arm of the anesthesia breathing circuit. The 
concentration of inhaled NO was continuously monitored 
at a location just proximal to the endotracheal tube by 
chemiluminescence (Chemiluminescence Monitor model 
42H; Thermo Environmental Instruments, Franklin, 
Mass.). The exhalation limb of the breathing circuit was 
likewise continuously monitored by chemiluminescence 
for nitrogen dioxide and NO x (toxic higher oxides of NO). 
Protocol for data collection. Twenty consecutive male 
patients undergoing aorta-coronary artery bypass for se- 
vere three-vessel coronary artery disease participated in 
the study. All patients underwent complete coronary 
artery revascularization, including reversed saphenous 
vein grafts to the right coronary artery system. Patients 
received preoperative medication of 0.1 ms/ks morphine 
sulfate and 0.4 mg scopolamine intramuscularly 1 hour 
before arrival in the operating room. Ongoing drug ther- 
apy for concomitant medical problems was continued as 
deemed appropriate by the attending anesthesiologist. 
Each patient was monitored with a five-lead electrocar- 
diogram, a radial arterial line, and a pulmonary artery 
thermodilution oximetric atheter (Abbott Laboratories, 
Chicago, Ill.) introduced through the right internal jugular 
vein. To accurately measure pulmonary venous outflow 
pressure (left atrial pressure [LAP]) for determination of
PVR, a catheter for LAP monitoring was introduced into 
the left atrium through the right superior pulmonary vein 
after the patient had been weaned from cardiopulmonary 
bypass. The LAP catheter was subsequently removed after 
completion of data collection and before chest closure. 
The anesthetic technique consisted of a high-dose nar- 
cotic (fentanyl) and relaxant (vecuronium) technique sup- 
plemented with intravenous midazolam. Inhalational 
anesthetic agents were administered only during cardio- 
pulmonary bypass. 
Data were collected in the operating room beginning 
approximately 20 minutes after completion of cardiopul- 
monary bypass but before chest closure. After weaning 
from bypass and protamine administration, all patients 
were in hemodynamically stable condition and demon- 
strated normal coagulation. No patients required cardiac 
pacing, antiarrhythmic therapy, or inotropic or vasoactive 
drug administration. No inhalational anesthetics were 
administered from the time of cessation of cardiopulmo- 
nary bypass throughout the period of data collection. 
The protocol for collection of data proceeded as fol- 
lows: Tidal volume was set at approximately 10 ml/kg and 
respiratory rate was adjusted to establish an arterial 
carbon dioxide tension of approximately 40 mm Hg and 
an arterial pH of approximately 7.40. 6 To avoid changes in 
pulmonary hemodynamics resulting from changes in ven- 
tilatory patterns, ventilator settings were not subsequently 
altered during the study period. Fraction of inspired 
oxygen was maintained at a mean of 0.97 (range 0.94 to 
0.99), and no patient had positive end-expiratory pressure 
applied at any point during the study period. Arterial 
oxygen tension (Po2) was therefore maintained at greater 
than 275 mm Hg throughout the study period to avoid any 
influence of hypoxemia on pulmonary vascular tone. 
Arterial and mixed venous blood gas samples were ob- 
tained at each point of data collection. The hemodynamic 
variables measured and recorded were heart rate, mean 
SAP, MPAP, central venous pressure, LAP, and ther- 
modilution CO (mean of three values). These allowed 
mathematic derivation of PVR, SVR, cardiac index, right 
ventricular stroke work index (RVSWI), and transpulmo- 
nary gradient (TPG). 
The protocol for data collection is shown in Fig. 1. After 
placement of the LAP line and with the patient in a 
hemodynamic steady state, baseline hemodynamic vari- 
ables were determined. NO at a concentration of 20 ppm 
was then added to the ventilatory circuit. After 10 minutes 
of inhaled 20 ppm NO, hemodynamic variables were 
determined. The concentration of inhaled NO was then 
increased to 40 ppm. After 10 minutes, hemodynamic 
variables were once again determined. Inhaled NO was 
then stopped. After 10 minutes, hemodynamic post- 
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inhaled NO data were collected. The LAP line was then 
removed under direct vision and its insertion site in the 
right superior pulmonary vein was determined to be 
hemostatic. Methemoglobin level was determined before 
and after data collection. 
See Appendix for formulas used for calculation of 
hemodynamic parameters. 
Statistical analysis. Statistical analyses were per- 
formed with a Macintosh Quadra 650 Computer (Apple 
Computer, Inc., Cupertino, Calif.) and StatView software 
(Brain Power, Inc., Calabasas, Calif.). Data are presented 
as mean + standard error of the mean. Statistical evalu- 
ation used standard analysis of variance in conjunction 
with the Student-Newman-Keuls multiple comparisons 
procedure. A p value less than 0.05 was accepted as 
statistically significant. 
Results 
The study population comprised 20 male patients, 
with subject demographics listed in Table I. All 
patients had a history of cigarette smoking; none, 
however, demonstrated clinical or radiographic evi- 
dence of significant chronic pulmonary disease. No 
subjects had preoperative pulmonary hypertension. 
All subjects were taking at least one aspirin daily 
before operation. 
Table II lists the arterial and mixed venous blood 
gas values along with the hemodynamic variables 
determined at each point of data collection. There 
were no changes in arterial pH, arterial Po2, or 
arterial carbon dioxide tension throughout the study 
period. Likewise, there were no significant changes 
in heart rate, central venous pressure, or LAP 
throughout the period of data collection. Methemo- 
globin level was unchanged after administration of 
inhaled NO. 
Inhaled 20 ppm NO produced a significant reduc- 
tion in MPAP without decrease in mean SAP. As 
shown in Fig. 2, 20 ppm NO produced a 24% 
decrease in MPAP: MPAP was reduced from to 29 
+_ 1 to 22 _+ 1 mm Hg (p < 0.05). Increasing the 
concentration of inhaled NO to 40 ppm produced a
small additional decrease in MPAP to 21 _+ 1 mm 
Hg. MPAP returned to 29 _+ 1 mm Hg after 
withdrawal of inhaled NO (p < 0.05 vs during 
inhalation; not different from before NO). On the 
other hand, mean SAP was not changed uring NO 
inhalation (Fig. 2). 
As shown in Fig. 3, these changes in MPAP 
were produced without significant changes in pul- 
monary arterial blood flow (CO) or pulmonary 
venous outflow pressure (LAP). The changes in 
pulmonary arterial pressure (MPAP) therefore 
occurred as a result of pulmonary vasorelaxation. 
In fact, as shown in Fig. 4, inhaled NO produced 
Table I. Patient demographics 
No. of patients 20 
Age (yr) 57 ± 6 
Body surface area (m 2) 1.8 + 0.05 
Aortic crossclamp time (rain) 91 ± 17 
Cardiopulmonary b pass time (rain) 124 ± 18 
Tidal volume (ml/kg) 10 ± 0.5 
Respiratory rate (breaths/min) 12 
Values are mean _+ standard error of the mean. 
a significant reduction in TPG. Before inhaled 
NO, the TPG was 21 _+ 1 mm Hg. This was 
significantly lowered with 20 ppm NO by 33% to 
14 _+ 1 mm Hg (p < 0.05). The TPG was 13 _+ 1 
mm Hg during administration of 40 ppm NO and 
returned to 21 _+ 1 mm Hg after NO administra- 
tion was stopped (p < 0.05 versus during inhala- 
tion of NO; not different from before NO). 
This pulmonary vasorelaxation produced a reduc- 
tion in PVR (Fig. 5). Inhaled 20 ppm NO signifi- 
cantly reduced PVR from 343 _+ 30 to 233 _+ 25 
dynes.see,  cm -5, a 32% reduction in PVR (p < 
0.05). This reduction in PVR was not greater with 40 
ppm NO. With cessation of NO administration, 
PVR returned to 342 _+ 30 dynes, sec. cm -5 (p < 
0.05 versus during NO; not different from before 
NO). At the same time, there was no change in SVR 
during NO administration (Fig. 5). 
These changes in PVR resulted in a significant 
reduction in RVSWI. As shown in Fig. 6, RVSWI 
was significantly reduced from 12.1 _+ 0.5 gm. m -2 
before inhalation of NO to 8.9 +_ 0.5 gm.m 2 
during inhalation of 20 ppm NO (p < 0.05). At 40 
ppm NO, RVSWI was 8.6 +- 0.5 gm" m -2. After 
inhaled NO was stopped, RVSWI returned to 12.2 
_+ 0.5 gm. m -2 (p < 0.05 vs during NO; not different 
from before NO). 
Discussion 
The results of this study demonstrate hat inhaled 
NO after aorta-coronary bypass operations pro- 
duced significant reductions in MPAP, TPG and 
PVR. In turn, these effects on the pulmonary circu- 
lation resulted in a significant reduction in RVSWI. 
In this group of patients without severe pulmonary 
hypertension, inhalation of 20 ppm NO lowered 
PAP to normal levels; the reductions in PVR and 
PAP were not augmented by increasing inhaled NO 
from 20 to 40 ppm. This pulmonary vasorelaxation 
was achieved without changes in SVR or mean SAP. 
Patients undergoing cardiac operations offered a 
unique opportunity to examine the influence of 
inhaled NO on PVR. A homogeneous group, pa- 
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Fig. 2. Effect of inhaled NO on MPAP and mean SAP (MAP). Inhaled NO produced a significant 
decrease in MPAP without change in mean SAP. Asterisk representsp < 0.05 versus before and after NO. 
Table II. Hemodynamic data 
Before 20 ppm NO 40 ppm NO After NO 
Temperature (°C) 37.3 ± 0.5 37.2 _+ 0.5 37.2 _+ 0.5 37.2 ± 0.5 
Hemoglobin (gm/dl) 9.6 _+ 0.3 9.7 ± 0.3 9.6 -+ 0.4 9.6 _+ 0.4 
Arterial pH 7.39 _+ 0.01 7.41 _ 0.01 7.39 -+ 0.01 7.40 ± 0.01 
Arterial Pco2 (mm Hg) 39 -+ 4 42 + 4 40 + 3 40 _+ 2 
Arterial Po 2 (mm Hg) 310 _+ 18 300 -+ 12 305 _+ 10 316 -+ 12 
Mixed Venous pH 7.33 _+ 0.01 7.35 -+ 0.01 7.33 +_ 0.01 7.34 ± 0.01 
Mixed venous Pco2 (ram Hg) 47 _+ 3 46 ± 4 45 _+ 3 46 ± 3 
Mixed venous Po 2 (ram Hg) 40 _+ 3 39 ± 3 41 ± 2 40 ± 3 
Heart rate (beats/min) 93 _+ 6 94 ± 6 92 _+ 5 93 ± 7 
CVP(mmHg)  10_+1 9+1 9 - -1  9±1 
LAP (mm Hg) 8 +- 1 8 ± 1 8 ± 1 8 ± 1 
MPAP (mm Hg) 29 _+ 1 22 +_ 1' 21 ± 1" 29 +- 1 
TPG (mm Hg) 21 ± 1 14 _ 1" 13 _+ 1' 21 ± 1 
CO (L/min) 4.9 ± 0.5 4.8 -+ 0.5 4.7 ± 0.5 4.9 -+ 0.5 
Mean SAP (mm Hg) 76 _+ 5 75 ± 6 75 +_ 5 75 +- 5 
Methem0globin (gm/dl) 1.8 ± 0.1 1.9 ± 0.1 1.9 _+ 0.1 1.9 ± 0.1 
Pco2, Carbon dioxide tension; CVP, central venous pressure; TPG, transpulmonary gradient. Values are mean -- standard error of the mean. 
*p < 0.05 vs before and after inhaled NO. 
tients undergoing aorta-coronary bypass grafting, 
could be studied. Control of many variables that 
affect PVR was available with this select group of 
patients. Surgical access allowed accurate measure- 
ment of pulmonary venous outflow pressure (LAP) 
for calculation of PVR. 7 Anesthesia nd mechanical 
ventilated of these patients allowed maintenance of 
a constant rate of ventilation and tidal volume to 
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Fig. 3. Effect of inhaled NO on CO and LAP. Inhaled NO produced no changes in pulmonary arterial f ow 
(CO) or pulmonary venous outflow pressure (LAP). These data indicate that the reduction i  MPAP was 
produced by pulmonary vasorelaxation. Asterisk represents p < 0.05 versus before and after NO. 
avoid mechanical lterations of PVR. s Furthermore, 
arterial Po 2 could be well controlled and changes in 
acid-base status could be avoided, s'9 
In our protocol, a standard cardiac anesthetic 
technique was employed. Intravenous anesthetic 
agents were administered only before cardiopulmo- 
nary bypass, and inhalational nesthetic agents were 
not administered after cessation of cardiopulmonary 
bypass until after the period of data collection. Any 
influence of anesthesia on PVR can therefore be 
assumed to have been held constant. Although the 
anesthetic technique may influence the response of 
the pulmonary vasculature to inhaled NO, this in- 
fluence was held constant during the period of data 
collection. In addition, to optimize clinical rele- 
vance, patients were examined early after operation. 
The principal intracellular mechanisms of pulmo- 
nary vasodilators are ultimately mediated through 
either guanosine Y,5'-cyclic monophosphate (cGMP) 
or adenosine 3',5'-cyclic monophosphate. 1° Pharma- 
cologic agents mediated by cGMP that have been 
employed as pulmonary vasodilators in cardiac surgi- 
cal patients include nitroglycerin and sodium nitro- 
prussiden; agents mediated by cyclic adenosine mono- 
phosphate include prostaglandin El, dobutamine, 
amrinone, and isoproterenol. 12-1s All of these agents 
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Fig. 4. Effect of inhaled NO on TPG. Asterisk represents p < 0.05 versus before and after NO. 
are administered intravenously, and all clinically pro- 
duce vasodilation of both the systemic and pulmonary 
vascular beds. In patients with increased PVR, such 
nonselective vasodilation may be hazardous: signifi- 
cant hypotension may result if the reduction of SVR is 
greater than the reduction in PVR. 1' 2 Such hypoten- 
sion may in fact be life-threatening if the SAP is 
lowered enough to decrease coronary arterial perfu- 
sion pressure, resulting in right ventricular ischemia 
and failure. 16' 17 Further, the clinical effectiveness of
intravenously administered pulmonary vasodilators i
often limited by the fact that they increase intrapul- 
monary shunt fraction and thereby lower arterial 
Po2 .is 
Inhaled NO may offer a significant advantage as a 
pulmonary vasodilator. Once administered into the 
alveoli by inhalation, it diffuses rapidly across the 
alveolar-capillary membrane into the subjacent vas- 
cular smooth muscle to stimulate guanylate cyclase, 
generating cGMP and producing pulmonary vascu- 
lar smooth muscle relaxation. 19' 2o Once NO diffuses 
through the smooth muscle cell into the capillary 
lumen, it is immediately bound to hemoglobin in 
erythrocytes as methemoglobin; the affinity of he- 
moglobin for NO is approximately 3000 times 
greater than the affinity of hemoglobin for oxygen. 2° 
Methemoglobin s reduced to nitrates by methemo- 
globin reductase, found in erythrocytes. It is esti- 
mated that most of the nitrates and nitrites found in 
blood result from the metabolism of endogenous 
NO. 2° In this way, the vasodilating actions of inhaled 
NO are focused in the pulmonary circulation; it is 
metabolized before it reaches the systemic irculation. 
Most of the human data relating to the use of 
inhaled NO have been obtained from patients with 
both hypoxemia nd pulmonary vasoconstriction. I -
haled NO has been used clinically as a pulmonary 
vasodilator in infants with persistent pulmonary hyper- 
tension. In such infants, severe pulmonary vasocon- 
striction is associated with hypoxemia nd systemic 
hypotension. By dilating the pulmonary circulation, 
inhaled NO has been shown to improve oxygenation 
and increase systemic blood pressure. TM22 Inhaled NO 
has also proved to be an effective pulmonary vasodi- 
lator in children with acute pulmonary insufficiency. 23
Although the pediatric pulmonary vascular bed is 
prone to avid pulmonary vasoconstriction, i haled NO 
has been shown to vasodilate hypoxic pulmonary va- 
soconstriction i adults as well. z4 In fact, the most 
extensive clinical experience with inhaled NO has been 
in patients with ARDS.  3' 4, 25-28 Inhalational adminis- 
tration of NO directs the agent into ventilated alveoli, 
where it acts locally to vasodilate. This local vasodila- 
tion diverts pulmonary blood flow away from poorly 
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Fig. 5. Effect of inhaled NO on pulmonary and SVR. Inhaled NO produced a significant reduction i  PVR 
without change in SVR. Asterisk represents p < 0.05 versus before and after NO. 
ventilated regions of the lung, thereby optimizing 
ventilation-perfusion matching. In most series of pa- 
tients with ARDS, inhaled NO is reported to simulta- 
neously improve oxygenation and reduce PAP. Be- 
cause hypoxemia is such an important cause of 
pulmonary vasoconstriction, however, it is unclear 
from these data what effect, if any, inhaled NO has on 
pulmonary vasoconstriction that is not associated with 
hypoxemia. Of particular interest, as many as one third 
of patients with ARDS have not shown improved 
oxygenation in response to inhaled NO. In these 
nonresponding patients, inhaled NO has minimal ef- 
fect on PAP. 3 
Unlike patients with ARDS, cardiac surgical pa- 
tients may have pulmonary vasoconstriction not 
associated with hypoxemia. Unfortunately, relatively 
few data are available regarding the use of inhaled 
NO after cardiac operations. When administered 
before operation to patients with congenital heart 
disease and pulmonary hypertension, inhaled NO 
lowered PAP without lowering SAP. 29 In postoper- 
ative pediatric ardiac surgical patients with severe 
pulmonary hypertension refractory to conventional 
therapy, inhaled NO lowered MPAP in 12 of 17 
patients. Administration of inhaled NO was associ- 
ated, however, with a significant decrease in mean 
SAP in four of these 17 patients (24%). 5 In adults 
with pulmonary hypertension after mitral valve re- 
placement, inhaled NO produced a modest reduc- 
tion in PAP9 ° Patients with pulmonary hyperten- 
sion from mitral valve disease frequently have 
structural changes in the pulmonary vascular bed, 
however, which may contribute to increased PVR 
yet may not be amenable to vasodilator therapy. In 
a study of 20 adult cardiac surgical patients, 16 of 
whom underwent single- or double-valve replace- 
ment and four of whom underwent coronary artery 
bypass grafting, the response to inhaled NO was 
found to be unchanged by cardiopulmonary b pass. 
The responsiveness of the pulmonary vascular bed 
to inhaled NO in these patients was variable, how- 
ever, and depended on the level of PVR before 
administration f inhaled NO. 31 In the first report of 
the use of inhaled NO in human beings, Pepke-Zaba 
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Fig. 6. Effect of inhaled NO on RVSWI. Asterisk represents p < 0.05 versus before and after NO. 
and coworkers 32 reported a significant fall in PVR in 
patients (including seven patients with mitral valve 
disease and three with ischemic heart disease) who 
breathed inhaled NO in the cardiac catheterization 
suite during preoperative evaluation. Lindberg and 
colleagues 33as well as Snow and colleagues, 34how- 
ever, reported minimal effect of inhaled NO on 
PVR after aorta-coronary b pass operations in adult 
cardiac surgical patients in whom the starting PAP 
was low. The findings of our study confirm that 
inhaled NO is an effective pulmonary vasodilator in 
adult cardiac surgical patients with elevated PAP 
(29 _+ 1 mm Hg) after cardiopulmonary bypass. 
Further, this pulmonary vasodilation was accom- 
plished in patients without hypoxemia. It is possible 
that the reduction of PAP and PVR found in our 
study but not found in the studies by Lindberg and 
associates 33and Snow and colleagues 34was a func- 
tion of the higher PAP in our study. The reasons for 
the higher pulmonary vascular tone in our study are 
unclear, but this higher PAP may reflect differences 
in anesthetic or perfusion techniques, duration of 
cardiopulmonary b pass, or the time interval after 
completion of cardiopulmonary b pass before data 
collection. 
Our study was designed to examine the acute 
effects of inhaled NO administration. One may not 
draw conclusions therefore regarding the effects of 
prolonged exposure. NO is a potentially toxic gas; 
inhalation of greater than 1000 ppm has been shown 
to cause acute lung injury in laboratory animals. 35 In 
human beings, NO is believed to cause silo-filler's 
disease, z° Prolonged administration of inhaled NO 
therefore requires chemiluminescence monitoring 
to accurately measure the concentration of inhaled 
NO and to measure the exhaled concentration of its 
toxic metabolite, nitrogen dioxide. Blood samples 
are also required to measure methemoglobin con- 
centration. During the brief administration of in- 
haled NO in our study, there were no changes in 
nitrogen dioxide or methemoglobin. Despite these 
potential toxicities, prolonged administration of in- 
haled NO to patients with ARDS in concentrations 
as great as 80 ppm for durations as long as 53 days 
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have not been found to produce toxic effects in the 
lung. 4 Nonetheless, a trial of inhaled NO was reported 
to precipitate pulmonary edema in a patient with 
stable heart failureY Of particular concern in cardiac 
surgical patients is the possibility that inhaled NO may 
depress myocardial contractility. Although no changes 
in CO were found with inhaled NO in our study, 
further investigation is required to determine the 
influence of inhaled NO on cardiac function. 
Net pulmonary vascular smooth muscle tone re- 
sults from the mechanistic balance of vasoconstric- 
tion and vasorelaxation. I  the normal ung, the low 
pulmonary vascular smooth muscle tone may be due 
at least in part to basal release of endothelium- 
derived NO. 37 The pulmonary vasoconstricting ef- 
fects of cardiopulmonary bypass are well recog- 
nized. After cardiopulmonary bypass, increased 
pulmonary vascular tone may be caused by in- 
creased levels of circulating or local vasoconstricting 
agonists. 3s Pulmonary vascular endothelial dysfunc- 
tion may contribute to this pulmonary vasoconstric- 
tion; impairment of endothelium-dependent cGMP- 
mediated pulmonary vasorelaxation has recently 
been described after cardiopulmonary b pass. 39 Be- 
cause inhaled NO achieves pulmonary vascular 
smooth relaxation independently of the endothelium, 
it may offer a mechanistic advantage for use as a 
pulmonary vasodilator after cardiopulmonary b pass. 
In summary, inhaled NO produced a significant 
reduction in both PAP and PVR in patients after 
cardiac operations without reducing SAP or SVR. 
In this study, there were no differences in the 
hemodynamic effects of 20 and 40 ppm NO. In 
patients with higher PVR and PAP, however, con- 
centrations as high as 80 ppm may be required. We 
conclude that inhaled NO may be clinically valuable 
as a "selective" pulmonary vasodilator for cardiac 
surgical patients. It may be particularly valuable for 
patients with dysfunction of the right side of the 
heart by selectively lowering right ventricular after- 
load, thereby optimizing function of the right side of 
the heart. 
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Discussion 
Dr. Jorge A. Wernly (Albuquerque, N.M.). I congratu- 
late Fullerton and associates on an elegant, well-con- 
trolled clinical study demonstrating the efficacy of NO in 
controlling PVR after cardiac operations. Specifically, I
congratulate Dr. Fullerton for a beautiful presentation. 
He has presented the data in a clear, eloquent, and precise 
manner. 
The study confirms that inhaled NO is able to selec- 
tively vasodilate the pulmonary artery circulation without 
decreasing SAP. As expected, these changes in PVR 
resulted in a significant substantial decrease in right 
ventricular work. There are few data on the effects of NO 
after cardiac operations. Most clinical studies have been 
done on patients who had pulmonary hypertension or 
ARDS with different degrees of hypoxic pulmonary vaso- 
constriction. In these patients, NO improves oxygenation 
and decreases the hypoxic vasoconstriction. By dilating 
vessels next to ventilated alveoli, NO distributes blood 
flow away from nonventilated areas, improving systemic 
oxygenation. It is unclear from these what direct effect NO 
has on general indexes of PVR. The patient undergoing 
cardiac operation, in contrast, offers a unique opportunity 
to observe the direct effects of NO on pulmonary vascu- 
lature. These patients can be safely instrumented, and 
most of the variables affecting PVR, namely po2, carbon 
dioxide tension, and pH, can be controlled. 
I have three comments and three questions. The first 
thing that caught my attention when I reviewed the 
manuscript, with which the authors graciously provided 
me well in advance, was that NO worked in all patients 
studied. From personal experience with NO in the pedi- 
atric population, I was prepared to accept hat NO did not 
modify PVR in a significant number of patients. Are we in 
the presence of pulmonary hypertension with a single 
cause? Do these findings help identify which mechanism is 
causing pulmonary vasoconstriction after cardiopulmo- 
nary bypass? 
Dr. Fullerton. To be honest, I do not know the answer 
to your question. I think that if one looks at how NO 
works, it requires intact intracellular mechanisms 
within the vascular smooth muscle. It is our working 
hypothesis that the vascular smooth muscle as well as 
the endothelium is injured in certain settings of lung 
injury. Perhaps in those patients the mechanism within 
the smooth muscle cells, specifically guanylate cyclase, 
is unable to respond to the administration of inhaled 
NO. If guanylate cyclase cannot make cGMP in re- 
sponse to NO, NO is ineffective. We deliberately chose 
a homogeneous group of patients, those undergoing 
coronary artery bypass. As we continue to collect data, 
it is my anecdotal observation that patients who have 
severe pulmonary hypertension from valvular disease 
respond much less favorably to inhaled NO. I wonder 
whether some of the vascular emodeling that goes on 
with chronic venous congestion in the left atrium, for 
instance, may affect these mechanisms within the 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 4 
Fullerton et aL 7 6 3 
smooth muscle cell, rendering such patients less respon- 
sive to NO. 
Dr. Wernly. If we accept hat the increase in PVR is a 
result of endothelium dysfunction, I wonder whether 
these findings will stimulate us to explore ways to better 
protect he endothelium during cardiopulmonary b pass. 
My second question deals with lack of changes in 
LAP. Recent clinical studies in patients with ARDS 
have demonstrated a modest yet significant decrease in 
occluded PAP, probably as a result of changes in LAP. 
In contrast, your patients did not demonstrate any 
changes in LAP. I wonder whether the fact that the 
pericardium was opened in all your patients explains 
the lack of decrease in LAP. As you know, there is a 
"volume competition" in the intact patient when the 
right ventricle dilates in response to increases in after- 
load, which obviously did not take place here. Also, do 
you think that transesophageal echocardiography could 
have demonstrated changes in heart chamber dimen- 
sions in response to NO? 
Dr. Fullerton. We deliberately studied patients in the 
operating room for just that reason, to minimize the 
number of confounding variables. I believe that it is an 
excellent suggestion to use transesophageal chocardiog- 
raphy to help get some other parameter to follow in terms 
of ventricular function. We have not employed that mo- 
dality, but it is an excellent idea. 
One of the reasons we believe in measuring LAP 
directly, rather than relying on wedge pressure, is that our 
data as well as data published by others have shown a 
dissociation of those two numbers in approximately 25% 
of paired measured samples. We therefore do not mea- 
sure the wedge pressure; rather, for the purposes Of 
studies like this, we have studied LAP directly. 
Dr. Wernly. My third question deals with the possibility 
that NO may depress myocardial contractility. I found it 
interesting that despite the beneficial effects of NO on 
right ventricular work, there were no beneficial changes in 
CO. Do you think that this is because these patients did 
not have right ventricular dysfunction? Or is it perhaps 
because the benefits were "canceled" by a subtle negative 
effect on myocardial contractility? 
Dr. Fullertou. I do not think that there is any way to 
answer that question from our data, but my gut feeling 
is that NO may well have a negative inotropic effect on 
the myocardium. I think that if you look at other studies 
in which pulmonary vasodilators have been ad]'ninis- 
tered there is typically an increase in CO as PVR falls. 
Consistently, however, both in patients with ARDS and 
now in this study in which NO was administered, CO 
has not changed. I therefore think that the reduction in 
right ventricular afterload may have been counterbal- 
anced by the negative inotropic effect of some circulat- 
ing element leaving the lungs and entering the myocar- 
dium. Unfortunately, our study was not able to address 
that issue. 
Dr. Wernly. I thank the Association for the privilege of 
discussing this presentation, which i believe is a significant 
contribution to our understanding of pulmonary circula- 
tion. 
Dr. Winfield J. Wells (Los Angeles, Calif.). You have 
hinted that you have data on patients with mitral disease 
and elevated PAP. Have you done these same studies on 
that group? 
Dr. Fullerton. In a relatively small number of patients, 
we have not found that NO has been very effective at 
all. There has been a very small reduction in PAP and 
a small reduction in PVR. My gut feeling is that it 
probably has something to do with the inherent differ- 
ences in this remodeling of the pulmonary circulation, 
which is of course well understood in mitral stenosis, 
that prevents those particular vessels from responding 
to NO. 
Dr. Wells. A follow-up is obviously to ask your thoughts 
about an experimental model that might be able to tell us 
why this agent is not working in this disease process. 
Dr. Fullerton. As you know, we have a couple of 
different models of acute lung injury ongoing in our 
laboratory, and our emphasis has been to try to get a 
better handle on why cGMP may not be generated in 
response to stimulation by NO. That is what we are 
working on, and although I do not know whether that will 
provide any insight into this, I am hopeful. 
Dr. Charles M. Rucker (Phoenix, Adz). I just wanted to 
follow up. When you mentioned that you think that 
perhaps there is a decrement in function of cGMP gua- 
nylate cyclase in patients with pulmonary hypertension, do 
you think there is any dysfunction i  NO synthase itself. If 
you do, do you think that it is related to inducible NO or 
constitutive NO? 
Dr. Fullerton. That is a hard question to answer. I have 
no personal knowledge, but judging from what others 
have written in the literature, I think that NO synthase is 
probably intact. In isolated lung preparations in which the 
perfusate is altered, the metabolites of NO that come out 
in the effluent appear to be unchanged espite infliction of 
a variety of forms of lung injury. 
Appendix 
Hemodynamic  formulas used are as follows: 
PVR (dynes. sec. cm - s) = 
MPAP - LAP 
CO 
× 80 (1) 
SVR (dynes. sec .cm 5) = 
MSAP - CVP 
CO 
x 8o (2) 
CO 
CI - BSA (3) 
CI 
RVSWI  (gm/m 2) = ~ × MPAP × 0.0144 (4) 
TPG (mmHg) = MPAP - LAP  (5) 
where MSAP is mean SAP, CVP is central venous 
pressure, CI is cardiac index, BSA is body surface 
area, and HR is heart  rate. 
